DLA Piper advises emocha Health in US$6.2 million Series A financing
DLA Piper represented emocha Health, a digital health company working to radically improve medication adherence amongst patients with chronic and infectious diseases, in its recently completed US$6.2 million Series A financing.
This new investment in emocha will further the strategic integration of deep human experience with technology so more healthcare stakeholders can use asynchronous video and other forms of communication to help people properly take their medications. emocha’s approach to real medication adherence directly supports the healthcare cost reduction and quality improvement goals of health plans, health systems, health departments, clinical researchers, employers and the individuals they cover and treat.
“We were pleased to bring our experience representing emerging healthcare technology companies in complex transactions to complete this financing for emocha, which will allow our client to continue working to improve medication adherence through its transformative digital solutions,” said Matthew Gorra, the DLA Piper partner who led the firm’s deal team.
The emocha Series A financing, which was oversubscribed by investors, was led by Claritas Health Ventures. Other participants included Healthworx, the innovation and investment arm of CareFirst BlueCross BlueShield, Kapor Capital, PTX Capital and TCP Venture Capital.
DLA Piper’s Emerging Growth and Venture Capital practice includes more than 200 lawyers in the US who provide strategic counsel to emerging companies in high-growth industries, including healthcare, insurance, biotech, manufacturing, communications, software and semiconductors. Over the last three years, DLA Piper has completed more than 2,100 financings totaling over US$31 billion.
DLA Piper's global Technology sector lawyers work across practice areas and offices to support technology clients – from startups to fast-growing and mid-market businesses to mature global enterprises – doing business around the world.